Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Novel Intra-articular Drug Delivery to Minimize Systemic Toxicity Associated with Currently Available TGCT Therapies First Set of Patient Data Expected in Second Half of 2021 REDWOOD CITY, Calif., May 26, 2021 (GLOBE NEWSWIRE) AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that the first patient has been enrolled in its Phase 2 clinical trial for the treatment of tenosynovial giant cell tumors (TGCT). The AmMax trial is an adaptive, multi-center, open-label Phase 2 proof-of-concept study to evaluate the safety, efficacy and pharmacokinetics of intra-articular injections of AMB-05X in patients with TGCT. (ClinicalTrials.gov Identifier: NCT04731675) TGCT is an aggressive tumor of the synovium primarily located in knee, hip, and ankle joints and caused by excessive production of CSF1. AMB-05X specifically inhibits the CSF1R pathw